Yi Luo

Yi Luo


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YCYun Chen
Yun Chen
HZHongyan Zhu
Hongyan Zhu
YLYi Luo
Yi Luo
STShuangmei Tong
Shuangmei Tong
YLYan Liu
Yan Liu
Drug resistance presents a formidable challenge in the realm of breast cancer therapy. Accumulating evidence suggests that enhancer of zeste homolog 2 (EZH2), a component of the polycomb repressive complex 2 (PRC2), may serve as a key regulator in controlling drug resistance. EZH2 overexpression has been observed in breast cancer and many other malignancies, showing a strong correlation with poor outcomes. This review aims to summarize the mechanisms by which EZH2 regulates drug resistance, with a specific focus on breast cancer, in order to provide a comprehensive understanding of the underlying molecular processes. Additionally, we will discuss the current strategies and outcomes of targeting EZH2 using both single agents and combination therapies, with the goal of offering improved guidance for the clinical treatment of breast cancer patients who have developed drug resistance.

1 December 2023 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
CGChao Gao
Chao Gao
YLYan Liu
Yan Liu
TZTinglin Zhang
Tinglin Zhang
YLYi Luo
Yi Luo
Jie GaoJie Gao
Jie Gao
YYYou Yin
You Yin
Current therapies for Alzheimer’s disease used in the clinic predominantly focus on reducing symptoms with limited capability to control disease progression; thus, novel drugs are urgently needed. While nanoparticles (liposomes, high-density lipoprotein-based nanoparticles) constructed with synthetic biomembranes have shown great potential in AD therapy due to their excellent biocompatibility, multifunctionality and ability to penetrate the BBB, nanoparticles derived from natural biomembranes (extracellular vesicles, cell membrane-based nanoparticles) display inherent biocompatibility, stability, homing ability and ability to penetrate the BBB, which may present a safer and more effective treatment for AD. In this paper, we reviewed the synthetic and natural biomembrane-derived nanoparticles that are used in AD therapy. The challenges associated with the clinical translation of biomembrane-derived nanoparticles and future perspectives are also discussed.

15 August 2024 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
WLWendanqi Liang
Wendanqi Liang
YLYi Luo
Yi Luo
AXAjing Xu
Ajing Xu
JCJianjian Chu
Jianjian Chu
WJWenbo Ji
Wenbo Ji
YYYou Yin
You Yin
Neurodegenerative diseases are devastating diseases that severely affect the health of people all over the world. RNA therapies have become one of the most promising critical drug treatments for neurodegenerative diseases due to their excellent gene and protein editing effects. However, the successful transport of RNA via the systemic route to the central nervous system remains one of the major obstacles in treating neurodegenerative diseases. This review will focus on therapeutic RNA that can successfully overcome the blood–brain barrier (BBB), with particular attention to small interfering RNAs (siRNAs), focusing on different types of neurodegenerative disease treatment strategies and accelerating their translation into clinical practice.

4 August 2025 in Materials Today Bio
Verified
Journal Article
Open access
JCJianjian Chu
Jianjian Chu
HHHui Hu
Hui Hu
WXWei Xu
Wei Xu
XLXinyu Lu
Xinyu Lu
HZHonglei Zhou
Honglei Zhou
YYYou Yin
You Yin
Alzheimer's disease (AD), a global health crisis exacerbated by aging populations, demands innovative therapeutic strategies. Curcumin, a natural compound with anti-aging and anti-inflammatory properties, holds promise for AD treatment but is hindered by poor bioavailability. Here, we developed curcumin-loaded nanovesicles (NV-CUR) derived from brain-homing B16 melanoma cells to overcome these limitations. NV-CUR enhanced the solubility, stability, and blood‒brain barrier (BBB) penetration of curcumin, enabling systemic delivery in aged 3 × Tg AD mice. Our 3R strategy for removing senescent cells, remodeling the neuroinflammatory microenvironment, and repairing neuronal damage was comprehensively validated. NV-CUR effectively cleared p16INK4a (P16)-positive senescent microglia, suppressed senescence-associated secretory phenotypes (SASP), and reduced neuroinflammation (IL-1β, IL-6, and TNF-α). Concurrently, NV-CUR diminished amyloid-beta plaques, attenuated Tau hyperphosphorylation, and restored hippocampal neuronal integrity. Cognitive assessments revealed significant improvements in memory and exploratory behavior, whereas biosafety evaluations confirmed that there was no systemic toxicity. This study establishes NV-CUR as a mechanistically innovative, clinically translatable nanomedicine that aligns with the 3R paradigm, offering a multifaceted approach to combat AD pathogenesis.

30 January 2006 in Chinese Physics Letters
Verified
Journal Article
Closed access
SJShao Jia-Ping
Shao Jia-Ping
HYHan Yan-Jun
Han Yan-Jun
Lai WangLai Wang
Lai Wang
JYJiang Yang
Jiang Yang
XGXi Guang-Yi
Xi Guang-Yi
YLYi Luo
Yi Luo

19 December 2023 in International Journal of Toxicology
Verified
Journal Article
Closed access
JWJing Wang
Jing Wang
TDTiantian Dong
Tiantian Dong
XGXinjiang Gong
Xinjiang Gong
DLDeli Li
Deli Li
JSJoanne Sun
Joanne Sun
HWHuazhang Wu
Huazhang Wu
Gastric cancer is one of the most common cancers worldwide, particularly in China, with over half a million new cases and over 400 thousand deaths in 2022. Zolbetuximab, a first-in-class investigational monoclonal antibody (mAb) targeting tumor-associated antigen CLDN18.2 which is highly expressed on gastric cancer cells, was recently reported to meet the primary endpoint in Phase III trial as first-line treatment in CLDN18.2 positive and HER2-negative gastric cancers. In the present study, we developed a humanized bispecific antibody (bsAb) CLDN18.2/4-1BB named PM1032. PM1032 activates immune cells via CLDN18.2 mediated crosslinking of 4-1BB, a potent stimulator of T/NK cells. It induced strong immunological memory in multiple tumor-bearing animal models, indicating significant potential as an effective treatment for CLDN18.2 positive cancers such as gastric cancer. Since liver and gastrointestinal (GI) related toxicities were reported in 4-1BB and CLDN18.2 targeting programs during the clinical development, respectively, extensive pharmacokinetics (PK) and safety profile characterization of PM1032 was performed in rhesus monkeys. PM1032 had a half-life comparable to a conventional IgG1 mAb, and serum drug concentration increased in a dose-dependent pattern. Furthermore, PM1032 was generally well tolerated, with no significant abnormalities observed in toxicity studies, including the liver and stomach. In summary, PM1032 demonstrated good PK and an exceptional safety profile in rhesus monkeys supporting further investigation in clinical studies.